Minimum to be relevant → Target to winStandard of care todayBenefit you deliverBest Phase III competitor – Asset B, expected

• Mortality benefitRelative reduction in CV death, on top of quadruple therapy›

  Standard of care today 0%Minimum to be relevant 8%Target to win 15%Asset B 8%

  The residual event risk on optimised therapy – the largest unmet need in the indication.

  0%Standard of care8%Minimum15%Target
• Hospitalisation reductionRelative reduction in HF hospitalisation›

  Standard of care today 0%Minimum to be relevant 12%Target to win 25%Asset B 14%

  The endpoint the payer tied to the top of the corridor.

  0%Standard of care12%Minimum25%Target
• Functional improvementSymptom-score points gained at 12 months›

  Standard of care today 3 ptsMinimum to be relevant 5 ptsTarget to win 10 ptsAsset B 4 pts

  34% of treated patients stay NYHA III on optimised therapy.

  3 ptsStandard of care5 ptsMinimum10 ptsTarget
• Durability of effectPatients maintaining benefit at 24 months›

  Standard of care today 62%Minimum to be relevant 65%Target to win 80%Asset B 70%

  Benefit holds while treatment continues; durability pays only where it shortens the regimen.

  62%Standard of care65%Minimum80%Target
• Safety and tolerabilityPatients still on therapy at 12 months›

  Standard of care today 88%Minimum to be relevant 88%Target to win 94%Asset B 86%

  Potassium and blood pressure cap titration today; removing one of them would be paid for.

  88%Minimum94%Target
• Administration burdenPatients on an all-once-daily regimen›

  Standard of care today 59%Minimum to be relevant 59%Target to win 90%Asset B 59%

  The strongest patient theme, and the one payers pay least for.

  59%Minimum90%Target
• Population coverageShare of the prevalent HF population in the label›

  Standard of care today 43%Minimum to be relevant 43%Target to win 75%Asset B 25%

  HFpEF is reached by one class; the segment is where a label could grow.

  43%Minimum75%Target